Aclaris Therapeutics Inc

NASDAQ:ACRS   12:43:57 AM EDT
17.01
-0.52 (-2.97%)
Earnings Announcements

Aclaris Therapeutics Reports Third Quarter Financial Results

Published: 11/08/2022 12:49 GMT
Aclaris Therapeutics Inc (ACRS) - Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update.
Q3 Revenue $19.0 Million.
Qtrly Loss per Share $0.30.
Q3 Earnings per Share View $-0.40, Revenue View $1.6 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $1.42 Million
Adjusted EPS is expected to be -$0.45

Next Quarter Revenue Guidance is expected to be $1.12 Million
Next Quarter EPS Guidance is expected to be -$0.43

More details on our Analysts Page.